Gland Pharma Ltd. · NSE:GLAND
Gland Pharma — Merger or Acquisition (November 2022)
13 slides from Gland Pharma's merger presentation, Nov 29, 2022
Slide 1: Gland Pharma Limited cover letter to exchanges
GLAND GLAND PHARMA LIMITED November 29, 2022 BSE Limited National Stock Exchange of India Limited Corporate Relationship Department Listing Department Phiroze Jeejeebhoy Towers Exchange Plaza, 5th floor 25th floor, Dalal Street Plot no. C-1, Block G, Bandra Kurla Complex Mumbai - 400 001 Bandra (Eas
Slide 2: Proposed Acquisition of Cenexi
GLAND PHARMA LIMITED Gland Pharma Limited Proposed Acquisition of Cenexi 29th November 2022 Cemcitibii lajectiM ■ Acquisition is subject to requisite approvals
Slide 3: Safe Harbor Statement
Safe Harbor Statement The Presentation is to provide the general background information about the Company’s objectives and goals as at the date of the Presentation. The information contained herein is for general information purposes only and based on estimates and should not be considered as a reco
Slide 4: Acquisition of Cenexi Strategic Objective
Gland Pharma Limited - Acquisition of Cenexi Strategic Objective: Expand our CDMO offerings in the European market, an addressable (dosage forms offered by Cenexi) FDF CDMO market of ~EUR 4 Bn in Europe and ~EUR 20 Bn globally (1) In line with our strategic roadmap of building a European manufacturi
Slide 5: Cenexi: Business Overview
Gland Pharma Limited - Acquisition of Cenexi Cenexi : Business Overview ➢ Founded in 2004, as a carve-out from Roche, Cenexi is a CDMO with sterile expertise and a track-record in ampoules, PFS and vials, and complex or niche formulations and/or dosage forms with a focus on high potent steriles and
Slide 6: Cenexi position in Pharma Value Chain
Gland Pharma Limited - Acquisition of Cenexi Cenexi position in Pharma Value Chain CDMO Cenexi Area of Operations cenexi Services cenexi CMO Development Activity Discovery Early Product Transfer & API(1) Marketing Research Development Lifecycle Services Production FDF(2) Production Packaging & Distr
Slide 7: Facilities Overview
Gland Pharma Limited - Acquisition of Cenexi Facilities Overview 4 complementary sites each with specialist technology and capabilities, available capacity to support long-term growth FONTENAY HÉROUVILLE BRAINE OSNY 1 F' ’r* ru.T2£jJ JEB gjjyi RsLWifl j ▪ Sterile-focused facility ▪ Capability in hig
Slide 8: Services Overview
Gland Pharma Limited - Acquisition of Cenexi Services Overview Cenexi Services: ‘Unavoidable partner’ to Cenexi customers, highly synergistic with CMO activity ▪ Dedicated, independent business with strong ties with Cenexi’s CMO activity © ✓ Development pipeline brings significant long-term and visi
Slide 9: Cenexi – Gland | A Win-Win Combination
Gland Pharma Limited - Acquisition of Cenexi Cenexi – Gland | A Win-Win Combination Become one of the leading sterile- focused CDMO globally with further ability GLOBAL SCALE to support investments in developing Cenexi’s European platform Gland to support and leverage Cenexi’s DEVELOPMENT leading de
Slide 10: Access to a blue-chip, global pharma and biotech customer base
Gland Pharma Limited - Acquisition of Cenexi Access to a blue-chip, global pharma and biotech customer base Specialty Pharma and Biotech Large Cap Pharma advAnz pharma' Pharmanovia •n BIOCODEX Debiophorm aspen rt & ■ J I H U d AstraZeneca HRA Iwrma! V QSE J: CHEPLA : Humanigeni: PHARM < ipsen nijwjl
Slide 11: Historical Financial Overview
Gland Pharma Limited - Acquisition of Cenexi Historical Financial Overview Revenue EBITDA CY19 (1) € 185.4m € 17.9m CY20 (1) € 195.3m € 22.1m CY21 (1) € 184.1m € 23.1m H1’CY22 (2) € 100.1m € 19.1m (1) Audited Financials (2) Limited Reviewed 10 (GLAND]
Slide 12: Purchase Consideration and funding
Gland Pharma Limited - Acquisition of Cenexi Purchase Consideration and funding 1 Enterprise Value of EUR 230 Mn for 100% shareholding of the company 2 Equity Value comes to EUR 120 Mn after deducting the adjusted net debt (1) 3 Transaction would be funded by internal resources with no recourse to t
Slide 13: Gland Pharma office addresses
GLAND Registered Office Corporate Office: Gland Pharma Limited Gland Pharma Limited Survey No. 143-148, 150 & 151 Plot No. 11 & 84, TSIIC Phase: IV Near Gandimaisamma 'X' Roads Pashamylaram (V), Patancheru (M), D.P. Pally, Dundigal Gandimaisamma Mandal Sangareddy District Medchal-Malkajgiri District